Pfizer Ltd. News, Corporate filings and Earnings/Conference Calls

Keep track of all breaking news and updates on Pfizer Ltd. from all sources in a single place.

Pfizer Ltd.

13 Nov 2025, 09:55AM

5043.50

0.56%

Pfizer Share Price Jumps Over 6% As Q2 Net Profit Increases

NDTV Profit

Pfizer Ltd. share price rose as much as 6.45% to Rs 5,339 apiece, the highest level since Oct 30.

Pfizer Ltd. is trading above its 200 day SMA of 4911.3

Pfizer Ltd.

12 Nov 2025, 03:37PM

5043.50

0.56%

Board Meeting

Pfizer Ltd - 500680 - Board Meeting Outcome for Outcome Of Board Meeting - Unaudited Financial …

BSE India

Pursuant to Regulations 30 and 33 of the Listing Regulations, we submit herewith the Unaudited Financial Results of the Company for the quarter and half year ended September 30, 2025, which were inter alia approved by the Board of Directors of the Company at their Meeting held today i.e., November 12, 2025, that commenced at 2.00 p.m. and concluded at 3.15 p.m.

pdf

Pfizer Ltd.

08 Nov 2025

5043.50

0.56%

Metsera accepts Pfizer's $10 billion acquisition bid in ongoing M&A battle

Business Standard

Pfizer appeared to have locked up the acquisition in September before Novo jumped in last week with an unsolicited offer, sparking a strategic fight

Pfizer Ltd.'s price crossed above 30Day SMA today

Pfizer Ltd.

03 Nov 2025

5043.50

0.56%

Board Meeting

Pfizer Ltd - 500680 - Board Meeting Intimation for Board Meeting To Consider And Approve The …

BSE India

Pfizer Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 12/11/2025 ,inter alia, to consider and approve This is to inform that a meeting of the Board of Directors of the Company is scheduled to be held on Wednesday, November 12, 2025 inter alia, to consider, approve and take on record the Unaudited Financial Results of the Company for the quarter and half year ended September 30, 2025.

pdf

Pfizer Ltd.

01 Nov 2025

5043.50

0.56%

Pfizer sues to stop rival bid for Metsera by Denmark's Novo Nordisk

Business Standard

Pfizer is suing over some unsolicited competition in its nearly $5 billion bid to buy the drugmaker Metsera. New York-based Pfizer said Friday after markets closed that it was suing Metsera and a third drugmaker, Denmark's Novo Nordisk, over a bid for Metsera that Novo announced Thursday. Novo said it planned to buy Metsera in a deal that could be worth up to $9 billion, and Metsera said the offer appeared to be superior to Pfizer's bid, which was announced in September. Metsera Inc has no products on the market, but it is developing potential oral and injectable treatments. That includes some potential treatments that could target lucrative fields for obesity and diabetes. Novo already has the treatments Wegovy and Ozempic on the market in those respective categories. Pfizer said the offer from Novo cannot be considered superior to its bid because it carries significant regulatory risk that makes it unlikely to be completed. Pfizer, which ended development of a potential pill to

Pfizer Ltd.'s price crossed above 30Day SMA today

Pfizer Ltd.

09 Oct 2025

5043.50

0.56%

Pfizer-Trump deal: What it means for drug prices and pharma giants in US

Business Standard

Pfizer has pledged to make some medicines available at lower prices for the Medicaid programme and in return gained relief from immediate import tariffs

Pfizer Ltd.'s price crossed above 30Day SMA today

Pfizer Ltd.

08 Oct 2025

5043.50

0.56%

Company Update

Pfizer Ltd - 500680 - Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018

BSE India

Certificate under SEBI (Depositories and Participants) Regulations, 2018 for the quarter ended September 30, 2025.

pdf

Pfizer Ltd.

03 Oct 2025

5043.50

0.56%

Pfizer's drug-price deal with Trump follows months of negotiation deadlock

Business Standard

Pfizer and the White House were deadlocked for months over lowering US drug prices, with Trump demanding quick results from drug executives right from the start of his second term

Pfizer Ltd. is trading at high day volume of 168.4K.

Pfizer Ltd.

01 Oct 2025

5043.50

0.56%

TrumpRx, Medicaid discounts and most-favoured-nation pricing: What Pfizer's agreement means

Business Line

President Donald Trump announced a deal with Pfizer to lower US drug costs by cutting Medicaid prices and aligning new drug prices with other high-income countries. The agreement also includes Pfizer onshoring all imported pharmaceuticals to avoid US tariffs.

Pfizer Ltd. is trading above its 200 day SMA of 4911.3

Pfizer strikes drug pricing deal with Trump administration, invests $70 bn in US

Business Line | 01 Oct 2025 2 more

Pfizer Ltd.

01 Oct 2025

5043.50

0.56%

Pfizer to lower prescription drug costs for Medicaid in deal with Trump

Business Standard

Drugmaker Pfizer has agreed to lower drug costs under a deal struck with the Trump administration, President Donald Trump said Tuesday, as he promised similar deals will be struck with other drugmakers facing a threat of tariffs. The announcement, which Trump made with Pfizer CEO Albert Bourla at the White House, came as the Republican president has for months sought to lower drug costs. It also came as Washington faced a federal government shutdown at midnight amid a standoff between Democrats and Republicans over health care and its costs. Under the agreement, New York-based Pfizer will charge most-favoured-nation pricing to Medicaid and guarantee that pricing on newly launched drugs, Trump said. That involves matching the lowest price offered in other developed nations. I can't tell you how big this is," the president said. I think," Bourla said, today we are turning the tide and we are reversing an unfair situation. Trump has been talking for months about the need to lower dru

Number of FII/FPI investors increased from 139 to 158 in Sep 2025 qtr.

Is Pfizer Ltd. worth buying?

212 Votes:

Buy 74.06%

Sell 14.62%

Hold 11.32%

36.27% Gain from 52W Low

High volume today

Pfizer Ltd. News, Corporate filings and Earnings/Conference Calls

Keep track of all breaking news and updates on Pfizer Ltd. from all sources in a single place.